Overall, disease relapse occurs in 40 to 75% of recipients of autologous hematopoietic stem cell transplants 10 to 40% of recipients of allogeneic hematopoietic stem cell transplants Overall, success (cancer-free bone marrow) rates are 30 to 40% for patients with relapsed, chemotherapy-sensitive lymphoma 20 to 50% for patients with acute leukemia Compared with chemotherapy alone, hematopoietic stem cell transplantation improves survival of patients with multiple myeloma.